Search

Your search keyword '"Shigeta, Keisuke"' showing total 288 results

Search Constraints

Start Over You searched for: Author "Shigeta, Keisuke" Remove constraint Author: "Shigeta, Keisuke"
288 results on '"Shigeta, Keisuke"'

Search Results

3. Effectiveness and safety of primary prophylaxis of G-CSF during chemotherapy for prostate cancer, Japanese clinical guideline for appropriate use of G-CSF: clinical practice guidelines for the use of G-CSF 2022

4. Effectiveness and safety of primary prophylaxis of granulocyte colony-stimulating factor during dose-dense chemotherapy for urothelial cancer: Clinical Practice Guidelines for the Use of G-CSF 2022

10. Table S2 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

11. FIGURE 2 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

12. Data from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

13. Figure S3 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

14. FIGURE 6 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

15. FIGURE 7 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

16. FIGURE 1 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

17. FIGURE 3 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

18. FIGURE 4 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

19. FIGURE 5 from Identification of MUC1-C as a Target for Suppressing Progression of Head and Neck Squamous Cell Carcinomas

20. IDENTIFICATION OF MUC1-C AS A TARGET FOR SUPPRESSING PROGRESSION OF HEAD AND NECK SQUAMOUS CELL CARCINOMAS

22. MUC1-C Dependence for the Progression of Pancreatic Neuroendocrine Tumors Identifies a Druggable Target for the Treatment of This Rare Cancer.

31. Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan

33. Pairing symmetry of superconductivity coexisting with antiferromagnetism

34. Realization of Berezinskii's superconductivity in quasi-one-dimensional systems

35. Effect of low FGFR3 but high CD8 T cell infiltrated immune micro-environment on treatment response with pembrolizumab in upper tract urothelial carcinoma.

36. Odd-frequency Superconductivity on a Quasi-one-dimensional Triangular Lattice in the Hubbard Model

42. Diagnostic Value of the Vesical Imaging-Reporting and Data System in Bladder Urothelial Carcinoma with Variant Histology

43. IDH2 stabilizes HIF‐1α‐induced metabolic reprogramming and promotes chemoresistance in urothelial cancer

48. Profiling the Biological Characteristics and Transitions through Upper Tract Tumor Origin, Bladder Recurrence, and Muscle-Invasive Bladder Progression in Upper Tract Urothelial Carcinoma

49. PD13-05 CHANGES WITH TIME IN PROGNOSTIC FACTORS IN LOCALIZED PROSTATE CANCER SURVIVORS AFTER LOW-DOSE-RATE PERMANENT SEED IMPLANT BRACHYTHERAPY WITH IODINE-125; CONDITIONAL SURVIVAL ANALYSIS

Catalog

Books, media, physical & digital resources